Patent 10562861 was granted and assigned to Sumitomo Dainippon Pharma Co., Ltd. on February, 2020 by the United States Patent and Trademark Office.
The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: